Department of Psychiatry, University College London, Wolfson Building, Middlesex Hospital, London W1N 8AA.
J Psychopharmacol. 1994 Jan;8(2):98-103. doi: 10.1177/026988119400800205.
One hundred and eighty three patients with DSM-III-R major depressive illness were allocated randomly to treatment with one of two new generation antidepressants, fluoxetine and lofepramine. Both patient groups had significantly lower mean scores on the Hamilton Depression Rating Scale (HDRS) 6 weeks after entry to the trial (p < 0.001), but there were no differences between the groups, either at baseline or after 6 weeks, in total HRDS score or in subscores for anxiety or suicidality. Anticholinergic side effects were commoner with lofepramine; adverse effects were on the whole mild and few patients dropped out because of them. This study does not support previous claims of specific adverse effects of fluoxetine on anxiety and suicidality.
183 例符合 DSM-III-R 重性抑郁障碍的患者被随机分配接受两种新型抗抑郁药——氟西汀和氯丙米嗪的治疗。两组患者在入组后 6 周时汉密尔顿抑郁评定量表（HDRS）的平均评分均显著降低（p＜0.001），但两组在基线或 6 周后时的总 HDRS 评分或焦虑或自杀性亚评分均无差异。氯丙米嗪的抗胆碱能副作用更常见；总的来说不良反应较轻，很少有患者因不良反应而退出。本研究不支持氟西汀对焦虑和自杀性具有特殊不良反应的先前说法。
